 REDWOOD CITY, Calif., Jan. 05, 2021 GLOBE NEWSWIRE -- Revolution Medicines, Inc. Nasdaq: RVMD, a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the 39th Annual J.P. Morgan Healthcare Conference. The conference, which will take place January 11-14, 2021, is being conducted with a virtual format. 